PensionDanmark Pensionsforsikringsaktieselskab Grows Stake in McKesson Corporation $MCK

PensionDanmark Pensionsforsikringsaktieselskab increased its position in shares of McKesson Corporation (NYSE:MCK) by 8.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,850 shares of the company’s stock after purchasing an additional 2,525 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in McKesson were worth $23,310,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of MCK. University of Texas Texas AM Investment Management Co. purchased a new position in McKesson during the 4th quarter valued at about $25,000. Swiss RE Ltd. purchased a new stake in shares of McKesson in the fourth quarter valued at about $26,000. State of Wyoming acquired a new stake in shares of McKesson in the second quarter valued at approximately $29,000. Kingdom Financial Group LLC. acquired a new stake in shares of McKesson in the fourth quarter valued at approximately $33,000. Finally, Birchwood Financial Partners Inc. acquired a new position in shares of McKesson during the 4th quarter worth approximately $33,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MCK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $875.00 target price on shares of McKesson in a report on Friday, May 8th. William Blair initiated coverage on McKesson in a research note on Tuesday, April 28th. They set an “outperform” rating on the stock. Robert W. Baird set a $1,015.00 target price on shares of McKesson in a research note on Thursday. Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday. Finally, Wells Fargo & Company decreased their price target on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $968.93.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted earnings of $9.93 per share, above the $9.56 consensus estimate, while revenue rose 7.7% year over year to $105.38 billion, exceeding expectations of $103.88 billion. Earnings also increased from $8.26 per share in the prior-year quarter. McKesson Fiscal Q1 Earnings Report
• Positive Sentiment: The company raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly above the prior outlook and near or above analyst expectations. Revenue guidance was set at approximately $423.6 billion-$439.7 billion. McKesson Raises Full-Year EPS Guidance
• Positive Sentiment: Pharmaceutical profit grew 19%, led by specialty medicine demand and oncology growth. Management also highlighted disciplined spending, supporting the improved earnings outlook. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: McKesson plans to repurchase up to $5 billion of shares and reportedly raised its dividend by 15%, providing additional potential shareholder returns. McKesson Fiscal 2027 EPS and Share Repurchase Plan
• Neutral Sentiment: McKesson’s Medical-Surgical Solutions business is being rebranded as Wellverse ahead of a planned spin-off and IPO. The move could unlock value, but its financial impact and timing remain uncertain. McKesson Medical-Surgical Rebrands as Wellverse

McKesson Trading Down 0.5%

Shares of NYSE MCK opened at $872.68 on Friday. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00. The company has a market cap of $102.17 billion, a P/E ratio of 23.35, a P/E/G ratio of 1.44 and a beta of 0.30. The stock has a fifty day moving average price of $798.08 and a 200 day moving average price of $840.76.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 371.86% and a net margin of 1.12%.The company had revenue of $105.38 billion for the quarter, compared to analysts’ expectations of $103.88 billion. During the same quarter in the previous year, the firm posted $8.26 earnings per share. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, sell-side analysts forecast that McKesson Corporation will post 44.28 EPS for the current fiscal year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date is Tuesday, September 1st. McKesson’s payout ratio is currently 8.53%.

Insider Activity

In other news, EVP Thomas L. Rodgers sold 2,388 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $1,817,482.92. Following the completion of the transaction, the executive vice president directly owned 3,090 shares in the company, valued at approximately $2,351,768.10. This represents a 43.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Michele Lau sold 3,550 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at $2,471,259.23. The trade was a 52.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 28,748 shares of company stock valued at $22,262,035. Corporate insiders own 0.06% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.